|Activity type||Activity value||Assay description||Source||Reference|
|CC50||> 12.39 uM||NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)||ChEMBL.||18579783|
|EC50 (functional)||= 0.447 uM||NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay||ChEMBL.||18579783|
|EC50 (functional)||= 1.776 uM||NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay||ChEMBL.||18579783|
|Species name||Source||Reference||Is orphan|
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.